Results 41 to 50 of about 58,205 (308)

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date

Cancer Management and Research, 2023
Pedro Luiz Serrano Uson Junior,1– 3 Mitesh J Borad1 1Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, AZ, USA; 2HCOR, Hospital do Coração, Sao Paulo, Brazil; 3Center for Personalized Medicine, Hospital Israelita Albert Einstein, Sao Paulo ...
Uson Junior PLS, Borad MJ
doaj  

Significance and Impact of Changing WHO Classification Systems on Glial Tumors with Special Reference to IDH1 Mutation in Resource-Limited Setups

Asian Pacific Journal of Cancer Biology, 2023
Objectives: To reclassify glial neoplasms according to the 2021 WHO CNS tumor classification and to study the expression pattern of Isocitrate dehydrogenase 1 (IDH1) mutation by immunohistochemistry(IHC) and to categorize these tumors on the basis of ...
Divya Singh, Vatsala Misra, Kachnar Varma   +2 more
doaj   +1 more source

NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort. [PDF]

Hematol Oncol
ABSTRACT In the AVALON cohort of relapsed/refractory AML treated with venetoclax plus hypomethylating agents, NPM1 and IDH1/2 mutations showed no significant impact on response or survival. These findings indicate that prognostic models for relapsed AML should consider treatment context rather than baseline mutation status.
Vetro C, Azzali I, Petracci E, Papayannidis C, Eleuteri E, Palumbo FE, Federico V, Fracchiolla N, Zappasodi P, Martelli MP, Giannini MB, Brunetti L, Palmieri R, Nanni J, Simonetti G, Guolo F, Minetto P, Maurillo L, Gigli F, Billio A, Todisco E, Martinelli G, Marconi G.   +22 more
europepmc   +2 more sources

Expression of LOC285758, a potential long non-coding biomarker, is methylation-dependent and correlates with glioma malignancy grade

Radiology and Oncology, 2017
Identifying the early genetic drivers can help diagnose glioma tumours in their early stages, before becoming malignant. However, there is emerging evidence that disturbance of epigenetic mechanisms also contributes to cell’s malignant transformation and
Matjasic Alenka, Popovic Mara, Matos Bostjan, Glavac Damjan   +3 more
doaj   +1 more source

Sustained Clinical Response to Ivosidenib in Previously Treated Patients with Advanced Intrahepatic Cholangiocarcinoma Harboring an IDH1 R132 Mutation: Two Case Reports

Case Reports in Oncology
Introduction: Patients with progressing intrahepatic cholangiocarcinoma (iCCA) harboring an isocitrate dehydrogenase 1 (IDH1) mutation who received ivosidenib showed a median progression-free survival (PFS) benefit of 1.3 months compared to placebo in ...
Christian Müller, Sabine Franke, Timo Reisländer, Verena Keitel, Marino Venerito   +4 more
doaj   +1 more source

IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution

Cancer Medicine, 2020
Background Selective IDH1 and IDH2 inhibitors have been approved for targeted therapy of acute myeloid leukemia. Clinical trials for solid tumors with IDH1 and IDH2 (IDH1/2) mutations are ongoing.
Erika F. Rodriguez, Federico De Marchi, Parvez M. Lokhandwala, Deborah Belchis, Rena Xian, Christopher D. Gocke, James R. Eshleman, Peter Illei, Ming‐Tseh Li   +8 more
doaj   +1 more source

Idh1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis [PDF]

, 2018
Introduction The gene encoding isocitrate dehydrogenase 1 (IDH1) is frequently mutated in several tumor types including gliomas. The most prevalent mutation in gliomas is a missense mutation leading to a substitution of arginine with histidine at the ...
De Wit, M. (Maurice), French, P.J. (Pim), Gao, Y. (Ya), Lamfers, M.L.M. (Martine), Linde, H.C. (Herma) van der, Salomons, G.S. (Gajja), Sillevis Smitt, P.A.E. (Peter), Struys, E. (E.), Willemsen, R. (Rob)   +8 more
core   +1 more source

Impact of IDH1 Mutation on Long-Term Survival in Patients with Diffuse Glioma

Central Asian Journal of Medical Sciences, 2019
Objectives: Diffuse brain gliomas are common primary brain tumor associated with a poor prognosis. In this study, we aimed to determine the impact of IDH1 mutation status on long term survival.
Enkhee Ochirjav, Tuul Baldandorj, Gheeyoung Choe, Bayarmaa Enkhbat   +3 more
doaj   +1 more source

A case of recurrent epilepsy-associated rosette-forming glioneuronal tumor with anaplastic transformation in the absence of therapy. [PDF]

, 2019
Rosette-forming glioneuronal tumor (RGNT) most commonly occurs adjacent to the fourth ventricle and therefore rarely presents with epilepsy. Recent reports describe RGNT occurrence in other anatomical locations with considerable morphologic and genetic ...
Corless, Christopher L, Ferris, Sean P, Grafe, Marjorie, Gultekin, Sakir H, Halfpenny, Aaron, Lawce, Helen, Lucas, Lora, Moore, Stephen, Nazemi, Kellie, Olson, Susan, Perry, Arie, Selden, Nathan, Solomon, David A, Woltjer, Randy, Wood, Matthew D   +14 more
core   +1 more source

Isoform-level gene signature improves prognostic stratification and accurately classifies glioblastoma subtypes. [PDF]

, 2014
Molecular stratification of tumors is essential for developing personalized therapies. Although patient stratification strategies have been successful; computational methods to accurately translate the gene-signature from high-throughput platform to a ...
Bi, Yingtao, Davuluri, Ramana V, Macyszyn, Luke, O'Rourke, Donald M, Pal, Sharmistha, Showe, Louise C   +5 more
core   +1 more source